Literature DB >> 18413427

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

B M K Biller1, A B Grossman, P M Stewart, S Melmed, X Bertagna, J Bertherat, M Buchfelder, A Colao, A R Hermus, L J Hofland, A Klibanski, A Lacroix, J R Lindsay, J Newell-Price, L K Nieman, S Petersenn, N Sonino, G K Stalla, B Swearingen, M L Vance, J A H Wass, M Boscaro.   

Abstract

OBJECTIVE: Our objective was to evaluate the published literature and reach a consensus on the treatment of patients with ACTH-dependent Cushing's syndrome, because there is no recent consensus on the management of this rare disorder. PARTICIPANTS: Thirty-two leading endocrinologists, clinicians, and neurosurgeons with specific expertise in the management of ACTH-dependent Cushing's syndrome representing nine countries were chosen to address 1) criteria for cure and remission of this disorder, 2) surgical treatment of Cushing's disease, 3) therapeutic options in the event of persistent disease after transsphenoidal surgery, 4) medical therapy of Cushing's disease, and 5) management of ectopic ACTH syndrome, Nelson's syndrome, and special patient populations. EVIDENCE: Participants presented published scientific data, which formed the basis of the recommendations. Opinion shared by a majority of experts was used where strong evidence was lacking. CONSENSUS PROCESS: Participants met for 2 d, during which there were four chaired sessions of presentations, followed by general discussion where a consensus was reached. The consensus statement was prepared by a steering committee and was then reviewed by all authors, with suggestions incorporated if agreed upon by the majority.
CONCLUSIONS: ACTH-dependent Cushing's syndrome is a heterogeneous disorder requiring a multidisciplinary and individualized approach to patient management. Generally, the treatment of choice for ACTH-dependent Cushing's syndrome is curative surgery with selective pituitary or ectopic corticotroph tumor resection. Second-line treatments include more radical surgery, radiation therapy (for Cushing's disease), medical therapy, and bilateral adrenalectomy. Because of the significant morbidity of Cushing's syndrome, early diagnosis and prompt therapy are warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413427      PMCID: PMC3214276          DOI: 10.1210/jc.2007-2734

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  106 in total

Review 1.  Cushing's syndrome.

Authors:  M Boscaro; L Barzon; F Fallo; N Sonino
Journal:  Lancet       Date:  2001-03-10       Impact factor: 79.321

2.  The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease.

Authors:  J Estrada; J García-Uría; C Lamas; J Alfaro; T Lucas; S Diez; L Salto; B Barceló
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

3.  Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit.

Authors:  L B Yap; H E Turner; C B T Adams; J A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2002-01       Impact factor: 3.478

4.  SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.

Authors:  C Bruns; I Lewis; U Briner; G Meno-Tetang; G Weckbecker
Journal:  Eur J Endocrinol       Date:  2002-05       Impact factor: 6.664

5.  Cushing syndrome due to ectopic adrenocorticotropic hormone secretion.

Authors:  J P Aniszewski; W F Young; G B Thompson; C S Grant; J A van Heerden
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

6.  Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome.

Authors:  J Krakoff; C A Koch; K A Calis; R H Alexander; L K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

7.  Transsphenoidal pituitary surgery in Cushing's disease: can we predict outcome?

Authors:  G H Chee; D B Mathias; R A James; P Kendall-Taylor
Journal:  Clin Endocrinol (Oxf)       Date:  2001-05       Impact factor: 3.478

8.  Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission.

Authors:  D A Rees; F W F Hanna; J S Davies; R G Mills; J Vafidis; M F Scanlon
Journal:  Clin Endocrinol (Oxf)       Date:  2002-04       Impact factor: 3.478

9.  Retinoic acid prevents experimental Cushing syndrome.

Authors:  M Páez-Pereda; D Kovalovsky; U Hopfner; M Theodoropoulou; U Pagotto; E Uhl; M Losa; J Stalla; Y Grübler; C Missale; E Arzt; G K Stalla
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 10.  [Cushing's disease and corticotrophic adenoma: results of pituitary microsurgery].

Authors:  A Stévenaert; G Perrin; D Martin; A Beckers
Journal:  Neurochirurgie       Date:  2002-05       Impact factor: 1.553

View more
  212 in total

1.  SOM230 in Cushing's disease complicated by poorly controlled diabetes mellitus.

Authors:  C Fiorentino; C Motta; D T Wolosinska; S Monti; F Mori; V Toscano
Journal:  J Endocrinol Invest       Date:  2011-10       Impact factor: 4.256

2.  Diagnostic and therapeutic challenge in the management of a patient with ectopic adrenocorticotropin secretion.

Authors:  F Sanguin; N Albiger; C Betterle; C Mian; R Gatti; E Rossi; F Mantero; C Scaroni
Journal:  J Endocrinol Invest       Date:  2010 Jul-Aug       Impact factor: 4.256

3.  Surgery: Remission after transsphenoidal surgery for Cushing disease.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Nat Rev Endocrinol       Date:  2010-06       Impact factor: 43.330

Review 4.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

Review 5.  Characterization of persistent and recurrent Cushing's disease.

Authors:  Nina K Sundaram; Alessia Carluccio; Eliza B Geer
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

6.  Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.

Authors:  S Cannavo; E Messina; A Albani; F Ferrau; V Barresi; S Priola; F Esposito; F Angileri
Journal:  Endocrine       Date:  2015-04-16       Impact factor: 3.633

Review 7.  Role of stereotactic radiosurgery in the management of pituitary adenomas.

Authors:  Frederic Castinetti; Jean Régis; Henry Dufour; Thierry Brue
Journal:  Nat Rev Endocrinol       Date:  2010-02-23       Impact factor: 43.330

8.  Quality of life in children and adolescents 1-year after cure of Cushing syndrome: a prospective study.

Authors:  Margaret F Keil; Deborah P Merke; Roma Gandhi; Edythe A Wiggs; Kathy Obunse; Constantine A Stratakis
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-17       Impact factor: 3.478

9.  Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.

Authors:  Jessica MacKenzie Feder; Isabelle Bourdeau; Sophie Vallette; Hugues Beauregard; Louis-Georges Ste-Marie; André Lacroix
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

10.  Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients <65 years old in the United States.

Authors:  Michael S Broder; Maureen P Neary; Eunice Chang; Dasha Cherepanov; William H Ludlam
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.